<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01676285</url>
  </required_header>
  <id_info>
    <org_study_id>0010/11</org_study_id>
    <nct_id>NCT01676285</nct_id>
  </id_info>
  <brief_title>Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis</brief_title>
  <acronym>CARE Cirrhosis</acronym>
  <official_title>Effect of Metoprolol Succinate in Cardiac Remodeling Related to Nonalcoholic Cirrhosis. Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with
      cirrhosis. It is suspected that this specific cardiac dysfunction contributes to the onset of
      complications in liver disease. The purpose of this prospective, randomized trial is to
      determine whether metoprolol succinate can revert cardiac dysfunction secondary to cirrhosis
      (cirrhotic cardiomyopathy), and prevent complications (renal dysfunction, mortality). A total
      of 100 patients with cirrhotic cardiomyopathy will be randomized (Group R) to receive
      metoprolol succinate or placebo; other 25 patients without cirrhotic cardiomyopathy (Group F)
      will only be followed up without medication. All patients will be evaluated in the beginning
      and again after six months. The assessment protocol includes clinical evaluation,
      electrocardiogram, echocardiogram, laboratory analysis and life quality questionaire. The end
      points will be cardiac remodeling, electrophysiologic changes, sympathetic activity,
      laboratory issue changes, renal function, quality of life, and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhotic cardiomyopathy (CMC) is defined as a chronic cardiac dysfunction in patients with
      cirrhosis. Moreover, it is characterized by an abnormal and blunted response to pathological
      or pharmacological stress in the absence of any other associated cardiac disease. The
      diagnostic criteria are: baseline increased cardiac output, attenuated myocardial contractile
      response to stress, diastolic dysfunction, and electrophysiological repolarization
      abnormalities. It is suspected that cardiac dysfunction in cirrhosis contribute to the onset
      of complications in liver disease. We will investigate the effect of metoprolol succinate in
      the reversal of cardiac dysfunction and prevention of complications of cirrhosis in patients
      with cirrhotic cardiomyopathy. Furthermore, we want to study the influence of presence of CMC
      in the evolution of cirrhotic patients. The study will be prospective, randomized,
      double-blind, and placebo-controlled. The sample consists of 125 patients aged between 18 and
      60 years old diagnosed with severe liver cirrhosis (Child B or C or MELD score above 10) with
      cirrhotic cardiomyopathy or not. Of these, 100 patients with cirrhotic cardiomyopathy will be
      randomized into two groups: group R1 (metoprolol succinate) and group R2 (placebo). Group F
      will consist of cirrhotic patients without cardiomyopathy and will not receive medication.
      Patients will be evaluated by clinical examination, resting electrocardiogram, 24-hour
      Holter, stress echocardiography and laboratory (brain natriuretic peptide (BNP),
      catecholamines, plasma renin activity, and troponin) at inclusion and after six months. The
      end points are: 1) Reversal of cardiac dysfunction in patients with cirrhotic cardiomyopathy,
      2) Development of hepatorenal syndrome, 3) Reversal of the electrophysiologic abnormalities,
      4)Changes in laboratory tests, and 5) Mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of systolic function</measure>
    <time_frame>six months</time_frame>
    <description>Systolic functional reserve is measured by aortic velocity time integral in echocardiographic at rest and stress with dobutamine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in left ventricular diastolic function</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>From randomization until six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of BNP, catecholamines, plasmatic renin activity</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From randomization until six months of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiologic modifications</measure>
    <time_frame>Six months</time_frame>
    <description>QT prolongation R-R variability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Cirrhotic Cardiomyopathy</condition>
  <condition>Cardiac Remodeling</condition>
  <arm_group>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol succinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group without cirrhotic cardiomyopathy, only follow up without randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol succinate</intervention_name>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <other_name>Selozok</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than 18 years old.

          -  must have signed the written informed consent.

          -  nonalcoholic cirrhosis.

        Exclusion Criteria:

          -  Betablockers intolerance;

          -  Diagnosis of other cardiomyopathy

          -  Chronicle renal disease (Creatinine &gt; 2.5)

          -  Heavy alcohol intake history

          -  Presence of other disease with possible cardiac implication (infiltrative or storage
             disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Bacal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sao Paulo School of Medicine</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2012</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Fernando Bacal</investigator_full_name>
    <investigator_title>MD; PhD</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>cirrhotic cardiomyopathy</keyword>
  <keyword>cardiac remodeling</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>metoprolol succinate</keyword>
  <keyword>betablockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

